Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Digital Realty Trust, Inc. (DLR) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

Digital Realty Trust, Inc.Trade
State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

Digital Realty Trust, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Digital Realty Trust, Inc. trades at $191.45 (market cap $70.79B), while State Street SPDR S&P Biotech ETF trades at $158.23. The key difference: Digital Realty Trust, Inc. pays a 2.55% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Digital Realty Trust, Inc. nearer its low. Which is the better fit depends on your goals.

DLRXBI
Market Cap
$70.79B
Sector
Real EstateBroad Market / Factor
52-Week High
$203.91$164.28
52-Week Low
$147.93$86.92
Enterprise Value
$89.50B
Dividend Yield
2.55%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Digital Realty Trust, Inc.

Digital Realty Trust (DLR) trades at $193.80, up 0.64% today, with a bullish technical signal from moving averages and support at $192. Recent Q2 2026 earnings beat expectations with core FFO of $2.13 per share, driven by record leasing and a $1.9 billion backlog. The company raised its 2026 guidance, reflecting strong AI-driven data center demand. Valuation ratios are elevated, with a P/E of 245.32 and P/S of 25.47, indicating premium pricing relative to earnings and sales.

DLR's outlook is positive due to robust AI infrastructure demand and raised guidance, but high valuation and interest rate sensitivity pose risks. Analyst consensus is bullish with a $216.56 price target, though net cash flow turned negative in 2025. Investors should weigh growth potential against execution risks in a competitive sector.

State Street SPDR S&P Biotech ETF

XBI, the SPDR S&P Biotech ETF, trades at $157.37, up 1.88% today, with a bullish technical signal from moving averages and strong momentum indicators. The ETF has surged nearly 17% in a month, driven by positive clinical trial news and increased M&A activity in the biotech sector. Analyst coverage is limited to one hold rating, reflecting cautious optimism amid high volatility.

Outlook remains positive due to sector tailwinds like AI-driven drug discovery and robust M&A, but risks include policy uncertainty and the fund's high beta. Investors should weigh the potential for continued growth against inherent volatility in small- and mid-cap biotech holdings.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Digital Realty Trust, Inc.

Digital Realty owns and operates nearly 300 data centers worldwide. It has more than 35 million rentable square feet across five continents. Digital's offerings range from retail co-location, where an enterprise may rent a single cabinet and rely on Digital to provide all the accommodations, to cold shells, where hyperscale cloud service providers can simply rent much, or all, of a barren, power-connected building. In recent years, Digital Realty has de-emphasized cold shells and now primarily provides higher-level service to tenants, which outsource their related IT needs to Digital. Digital Realty has also moved more into the co-location business, increasingly serving enterprises and facilitating network connections. Digital Realty operates as a real estate investment trust.

Read more on DLR

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI